

CLINICAL PRACTICE

## Atopic Dermatitis

Hywel C. Williams, Ph.D.

*This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.*

**A 10-year-old girl with atopic dermatitis reports itching that has recently become relentless, resulting in sleep loss. Her mother has been reluctant to treat the girl with topical corticosteroids, because she was told that they damage the skin, but she is exhausted and wants relief for her child. How should the problem be managed?**

### THE CLINICAL PROBLEM

From the Center of Evidence-Based Dermatology, Queen's Medical Center, University of Nottingham, Nottingham, United Kingdom. Address reprint requests to Professor Williams at the Center of Evidence-Based Dermatology, Queen's Medical Center, University of Nottingham, Nottingham NG7 2UH, United Kingdom, or at [hywel.williams@nottingham.ac.uk](mailto:hywel.williams@nottingham.ac.uk).

N Engl J Med 2005;352:2314-24.

Copyright © 2005 Massachusetts Medical Society.

Atopic dermatitis (or atopic eczema) is an itchy, inflammatory skin condition with a predilection for the skin flexures.<sup>1</sup> It is characterized by poorly defined erythema with edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in the chronic stage (Fig. 1A and 1B). Although termed atopic, up to 60 percent of children with the clinical phenotype do not have demonstrable IgE-mediated sensitivity to allergens,<sup>2</sup> an observation that led the World Allergy Organization to propose a revised nomenclature.<sup>3</sup> Approximately 70 percent of cases of atopic dermatitis start in children under five years of age,<sup>4</sup> although 10 percent of cases seen in hospital settings start in adults.<sup>5</sup> Asthma develops in approximately 30 percent of children with atopic dermatitis, and allergic rhinitis in 35 percent.<sup>6</sup>

### DIAGNOSTIC CRITERIA

Atopic dermatitis is difficult to define because of its variable morphology and distribution and its intermittent nature. Several diagnostic criteria have been developed.<sup>7</sup> Consensus criteria for the main clinical features of atopic dermatitis<sup>8</sup> have led to a short list of reliable and valid discriminators that are used worldwide<sup>9</sup> (Table 1).

Assessing disease severity is problematic when there is no objective marker.<sup>10</sup> The many severity scales used in clinical trials are generally not suitable for rapid assessment in the clinic.<sup>11</sup> The presence or absence of sleep disturbance, the number and location of involved sites, and the clinical course are the indicators of severity that probably provide the best basis for making decisions about treatment.<sup>12</sup>

### PREVALENCE, COST, AND PROGNOSIS

According to the International Study of Asthma and Allergies in Childhood, the prevalence of symptoms of atopic dermatitis in children six or seven years of age during a one-year period varied from less than 2 percent in Iran and China to approximately 20 percent in Australia, England, and Scandinavia.<sup>13</sup> A high prevalence has also been found in the United States.<sup>14</sup> In the United Kingdom, one population survey of 1760 affected children from one to five years of age found that 84 percent of cases were mild, 14 percent were moderate, and 2 percent were severe.<sup>15</sup>

Studies suggest that atopic dermatitis imposes a high economic burden,<sup>16</sup> with out-of-pocket expenses and overall costs that are similar to those for the treatment of asthma.<sup>17</sup> Causes of family stress related to caring for children with moderate or severe



atopic dermatitis (e.g., sleep deprivation, loss of employment, time-consuming treatment, and financial costs) may rival those related to caring for children with diabetes mellitus type 1.<sup>18</sup>

Approximately 60 percent of patients with childhood atopic dermatitis are free of symptoms in early adolescence,<sup>19</sup> although up to 50 percent may have recurrences in adulthood.<sup>20</sup> Early-onset disease, severe early disease, concomitant asthma and hay fever, and a family history of atopic dermatitis may predict a more persistent course.<sup>4</sup> One recent cohort study of 1314 German children showed that the prognosis was related to disease severity and

**Table 1. Criteria for the Diagnosis of Atopic Dermatitis.\***

The diagnosis requires evidence of itchy skin (or parental report of scratching or rubbing) plus three or more of the following:

- History of involvement of the skin creases (e.g., fronts of elbows, backs of knees, fronts of ankles, and areas around the neck or eyes)
- History of asthma or hay fever (or history of atopic disease in a first-degree relative if the child is under four years of age)
- History of generally dry skin in the past year
- Onset in a child under two years of age (criterion not used if the child is under four years of age)
- Visible flexural dermatitis (including dermatitis affecting the cheeks or forehead and outer aspects of limbs in children under four years of age)

\* Adapted from Williams et al.<sup>9</sup>

atopic sensitization, as evidenced by elevated serum levels of IgE antibodies to food and inhalant allergens at two years of age.<sup>21</sup>

#### CAUSES

Atopic dermatitis is probably a complex disease relying on the interplay of several factors.<sup>22</sup> Several genes have been identified that may explain some cases.<sup>23</sup> Genetics alone, however, cannot explain the results of studies of migrant populations that show, for example, that Jamaican children living in London are twice as likely to have atopic dermatitis as Jamaican children living in Jamaica; the increased risk of atopic dermatitis in smaller families and among higher social classes; and the rising prevalence of atopic dermatitis in some countries. These observations suggest a key role for the environment in mediating disease expression.<sup>24</sup> Whereas allergens such as house-dust mites and foods may be important in some cases, nonallergic factors such as rough clothing, *Staphylococcus aureus* infections, exposure to microbes during infancy, excessive heat, and exposure to irritants that disrupt the function of the skin barrier may also be important. Mechanisms for and implications of the possible prevention of atopic dermatitis are reviewed elsewhere.<sup>25,26</sup>

#### STRATEGIES AND EVIDENCE

##### DIAGNOSIS

Skin biopsy is of little value in the diagnosis of atopic dermatitis; instead, diagnosis is based on clinical features<sup>7-9</sup> (Table 1). The differential diag-

nosis depends on age and the country of residence (Fig. 2 and Table 2). Because of their high negative predictive value (above 95 percent), negative skin-prick or radioallergosorbent tests for foods and environmental allergens may be useful for assessing the contribution of allergies to disease expression in children with severe disease.<sup>27</sup> Positive tests are less useful, with positive predictive values of about 40 percent.<sup>27</sup>

Concomitant food allergy may be manifested as urticaria and gastrointestinal symptoms and may not necessarily exacerbate atopic dermatitis. Double-blind, placebo-controlled food challenges are the standard for diagnosing associated food allergy, but they are time consuming and not available in many hospitals.

The clinical utility of patch testing with airborne allergens is still unclear.<sup>28</sup> Patch tests are useful for excluding a diagnosis of suspected superimposed allergic contact dermatitis.<sup>29</sup>

#### TREATMENT

##### *Topical Corticosteroids*

One systematic review identified 83 randomized controlled trials of the use of topical corticosteroids in atopic dermatitis.<sup>30</sup> Vehicle-controlled studies lasting less than one month indicate that approximately 80 percent of people report good, excellent, or clear responses with topical corticosteroids, whereas 38 percent of persons in control groups reported such responses.

Potency of topical corticosteroids is classified by the potential for vasoconstriction—a surrogate for clinical efficacy and skin thinning (Table 3). In general, only preparations that have very weak or moderate strength are used on the face and genital area, whereas those that have moderate or potent strength are used on other areas of the body.<sup>31</sup> Lower-potency corticosteroids may be sufficient on all areas of the body in younger children. Preparations are typically used in bursts of three to seven days in order to achieve control. There is little difference in outcome between short-term use of potent preparations or longer use of weaker preparations in children with mild-to-moderate disease.<sup>32</sup> Lichenified atopic dermatitis requires more potent preparations for longer periods.

Long-term studies of moderate-to-potent preparations in children are scarce. One study of 231 children with stabilized atopic dermatitis randomly assigned to receive twice-weekly 0.05 percent fluticasone propionate (plus emollients) or vehicle alone plus emollients for 16 weeks showed that patients in the control group were more likely, by a factor of 8, to have a relapse (95 percent confidence interval, 4.3 to 15.2).<sup>33</sup> A four-month trial of persons 12 to 64 years of age with moderate-to-severe disease showed that the application of fluticasone to previously active and new sites of atopic dermatitis for two consecutive days each week reduced flares significantly, as compared with a group receiving an emollient only.<sup>34</sup>

Reduced efficacy of topical corticosteroids may be related to disease severity rather than to glucocorticoid resistance.<sup>35</sup> There is little evidence that the application of topical corticosteroids twice a day is more effective than once-daily applications,<sup>36</sup> and more frequent use may cause more local side effects.

A main concern with the use of topical corticosteroids is irreversible skin thinning. Although thinning is possible, the concern on the part of patients (and parents) is often well out of proportion to the true risk.<sup>37</sup> Although inappropriate use of potent preparations can cause skin thinning, four 16-week randomized trials did not show any clinically significant skin thinning,<sup>32-34,38</sup> and a 1-year study showed no significant effect on collagen synthesis.<sup>39</sup> A one-year study of unrestricted continual use of a potent corticosteroid on the limbs and trunk, a weak preparation on the face, or both showed that striae developed in 3 of 330 adults with moderate-to-severe atopic dermatitis.<sup>40</sup> Similar studies in children are lacking. Other possible side effects of cor-



**Figure 2. Discoid (Nummular) Eczema in an Infant.**

This pattern of eczema is frequently associated with atopic dermatitis and is often confused with ringworm infection.

**Table 2. Differential Diagnosis of Atopic Dermatitis.**

Diagnosis	Description
Seborrheic dermatitis of infancy	Red, shiny, relatively well-demarcated eruptions typically involving the diaper area are present in infants four months of age or younger. The lower abdomen and armpits may also be involved, and scalp scaling (cradle cap) may be present. The infant appears comfortable. The condition clears within a few months.
Adult-type seborrheic dermatitis	Poorly defined erythema due to overgrowth of or sensitivity to malassezia yeasts is present in seborrheic areas (i.e., sides of nose, eyebrows, external ear canal, scalp, front of chest, axillae, and groin creases).
Discoid (nummular) eczema	Circular "cracked" areas of erythema 1 to 5 cm in diameter are present initially on the limbs, often with secondary infection (Fig. 2). In children, discoid eczema is most commonly associated with atopic dermatitis and is often confused with tinea (ringworm). In adults, it may be associated with excessive skin dryness and secondary infection with <i>Staphylococcus aureus</i> .
Irritant contact dermatitis	Cumulative damage to the skin barrier from irritants such as soaps and detergents is present. The clinical appearance can be identical to that of atopic dermatitis, but location at sites of maximal exposure (e.g., fingers) may be helpful in making the diagnosis. Some degree of irritant contact dermatitis is common in persons with atopic dermatitis (e.g., in babies, around the mouth, owing to saliva and wet food, and in the diaper area, owing to urine).
Allergic contact dermatitis	A hypersensitivity reaction exists after sensitization to specific substances (e.g., the nickel in jewelry, the rubber in gloves, or the glues in some shoes). Localization may suggest this diagnosis, but patch tests are needed to definitively establish it. This diagnosis may coexist with atopic dermatitis.
Frictional lichenoid dermatitis	Shiny papules occur at elbows, knees, and backs of hands, probably related to friction. The diagnosis may be common, and may be more so in patients with atopic dermatitis.
Other exogenous skin conditions	
Scabies	Infestation may produce nonspecific eczematous changes on the entire body. Burrows and pustules on palms, soles, genitalia, and between fingers help to establish diagnosis.
Onchocerciasis	The chronic phase may be accompanied by widespread itching and lichenification of the skin similar to those seen in cases of chronic atopic dermatitis.
Insect bites	Secondary eczematous changes may develop in the area of the bites, especially on the limbs, and may be confused with atopic dermatitis.

ticosteroids include facial telangiectasia and glaucoma from periocular use (rarely reported in adults).

Secondary adrenal suppression and the suppression of growth resulting from systemic absorption of topical corticosteroids are also concerns, although clinically relevant adrenal suppression is very rare.<sup>41</sup> One study involving children with atopic dermatitis did not find any relationship between height velocity and the use of mild-potency as compared with moderate-potency topical corticosteroids.<sup>42</sup> Another study showed biochemical evidence of suppression of the hypothalamic-pituitary-adrenal axis only in children with atopic dermatitis who used potent or very potent topical corticosteroids and in those who had received glucocorticoids from other routes, and not in those who had used topical corticosteroids of mild or moderate strength for a median of 6.9 years.<sup>35</sup>

#### *Emollients*

There is no evidence that emollients improve atopic dermatitis directly. However, emollients are widely used because they improve the appearance and symptoms of the dry skin (xerosis) associated with this condition.<sup>30,31,43</sup> One study has shown that emollients may reduce the need for topical corticosteroids by approximately 50 percent,<sup>44</sup> and another study found that emollients enhanced the response to treatment with topical corticosteroids.<sup>45</sup> There is little basis for suggesting the use of one emollient over another, and the preference of the patient is probably the most important factor.<sup>31</sup>

#### *Topical Calcineurin Inhibitors*

Topical tacrolimus and pimecrolimus have both been shown to be effective in vehicle-controlled studies. For 1 percent pimecrolimus, the rate ratio

**Table 3. Therapeutic Interventions for Atopic Dermatitis.**

Intervention	Use	Recommendations	Anticipated Benefits	Potential Harms	Comments
Topical corticosteroids*	First-line treatment for patients of all ages with moderate-to-severe atopic dermatitis	Use the lowest effective potency; use only mild preparations on the face, neck, and intertriginous areas; once daily is probably as effective as twice daily; use for the duration of a flare; use intermittently (e.g., twice a week) Use potent preparations intermittently (e.g., twice a week) to reduce flares in moderate-to-severe disease; do not use continually, because of the possibility of skin thinning	Reduced itching and improvement in sleep, in the appearance of the skin, in self-esteem, and in quality of life (the magnitude of the benefit depends on the potency and on the duration and the site of application, as well as on the type of vehicle base; occlusion may enhance response)	Short-term — stinging on application (for potent preparations) Medium- to long-term — local complications (e.g., skin thinning, striae, glaucoma from prolonged periocular use, contact sensitization, and tolerance) and systemic effects (e.g., suppression of the hypothalamic–pituitary–adrenal axis and Cushing’s syndrome)	Optimal methods of use (in terms of potency, frequency, and duration of application) are unclear
Emollients†	First-line treatment for patients of all ages with very mild atopic dermatitis; adjunctive therapy for use with other topical or systemic treatments	Use to reduce symptoms from dry skin associated with atopic dermatitis, especially after inflammation has been treated with topical corticosteroids; thicker emollients are needed for thicker skin such as that on the hands and feet; apply greasier emollients in the direction of the hair to avert occlusion of hair follicles	Reduced skin dryness, itching, and penetration of skin by irritants and allergens; prevention of skin cracking; possible reduced need for topical corticosteroids; and possible enhanced response when used with topical corticosteroids	Stinging on application; a shiny residue on the face and hands may mark objects	Emollients may trap water in the skin (white soft paraffin), introduce water to the skin directly (aqueous cream), or increase the water-holding capacity of the skin (urea); permit patient to choose preparation
Topical tacrolimus	For people over two years of age (0.03% ointment) or 16 years of age or older (0.1% ointment) with moderate-to-severe atopic dermatitis unresponsive to or intolerant of topical corticosteroids	Use twice daily until symptoms resolve; use intermittently or early to prevent flares; do not use when infection is present	Reduced itching and improvement in sleep, in the appearance of the skin, in self-esteem, and in quality of life (magnitude of benefit with the use of 0.1% ointment probably equivalent to that with use of a potent topical corticosteroid, whereas benefit is less with 0.03% ointment)	Short-term — mild stinging or burning on application (approximately 43 percent for 0.1% ointment and 40 percent for 0.03% ointment), normally improves after a week; safety profile based on five years of use appears good Long-term (greater than five years) — safety unknown; use with caution with excess exposure to ultraviolet light	May be especially useful on delicate sites such as the face, neck, and axillae, where local skin thinning from frequent use of topical corticosteroids might be increased; the efficacy is unclear in people unresponsive to or intolerant of topical corticosteroids; can probably be used concurrently with topical corticosteroids applied to other body sites

Topical 1% pimecrolimus	For people over two years of age with mild-to-moderate atopic dermatitis unresponsive to topical corticosteroids	Use twice daily until symptoms resolve; use intermittently to reduce the severity and frequency of flares or use early to prevent flares	Reduced itching and improvements in sleep, in the appearance of the skin, in self-esteem, and in quality of life (magnitude of the benefit is less than that with a potent topical corticosteroid)	Short term — mild stinging or burning on application occurs in approximately 17 percent of patients and normally improves after a week; do not use when infection is present; safety profile based on five years of use appears good Long-term (greater than five years) — safety unknown; use with caution with excess exposure to ultraviolet light	The efficacy is unclear in people unresponsive to or intolerant of topical corticosteroids; may be useful on delicate sites such as the face
Oral antihistamines (non-sedating and sedating) ‡	Adjunctive therapy	Unclear	Possible reduced itching and improved sleep	Drowsiness	Frequently used, but evidence of benefit is unconvincing
Refined-coal tar	For patients with mild-to-moderate atopic dermatitis	Use twice daily on affected areas	Reduced itching, redness, and lichenification	Itching and stinging on application in approximately 17 percent of patients; odor; staining of skin and clothes	Data are based on one randomized controlled trial that compared refined-coal tar with 1% hydrocortisone; other tar preparations might also be effective, but irritation and cosmetic acceptability from odor and staining may be an issue
Topical doxepin	Adjunctive therapy for patients older than 12 years	Apply cream thinly 3 or 4 times a day (maximum, 12 g daily)	Short-term reduced itching	Drowsiness; transient stinging and burning on application	There is some evidence of reduced itching in the first 24 to 48 hours, but no evidence that symptoms and disease activity improved over a longer period
Oral corticosteroids §	For patients with a flare of severe atopic dermatitis	Use intermittently	Relief from itching and skin redness and infiltration, and reduced oozing	Short-term — increased appetite, psychosis, dyspepsia Long-term — hypertension, osteoporosis, adrenal suppression, striae, muscle atrophy	There is no evidence from randomized trials, but clinical experience suggests short-term use in instances of severe flare, followed by specialist support; the optimal dosage is unknown

\* Three strengths of corticosteroids are available — mild (e.g., 1% hydrocortisone), moderate (e.g., 0.05% clobetasone butyrate), and potent (e.g., 0.05% fluticasone propionate).  
 † Examples of emollients useful for the treatment of atopic dermatitis include aqueous cream, a 50:50 mixture of white soft paraffin and liquid paraffin, and various proprietary brands.  
 ‡ Non-sedating antihistamines include loratadine, 10 mg, and cetirizine, 10 mg; sedating antihistamines include chlorpheniramine maleate, 4 mg at night, for adults.  
 § Prednisolone may be used at a starting dose of 0.5 mg per kilogram of body weight, tapered over two to three weeks.

for the proportion of patients clear or almost clear of atopic dermatitis at three weeks in five vehicle-controlled trials involving 783 patients was 2.72 (95 percent confidence interval, 1.84 to 4.03).<sup>46</sup> For 0.03 percent and 0.1 percent tacrolimus, the rate ratios for the proportion of patients who were clear or who had excellent improvement at 12 weeks were 4.50 (95 percent confidence interval, 2.91 to 6.96) and 5.62 (95 percent confidence interval, 3.67 to 8.61), respectively, in three vehicle-controlled trials involving 656 patients.<sup>46</sup> Short-term studies suggest that 0.1 percent topical tacrolimus may be similar in strength to potent topical corticosteroids,<sup>46</sup> whereas topical pimecrolimus is considerably weaker.<sup>40,47</sup>

Few long-term studies compare intermittent use of topical calcineurin inhibitors with intermittent use of topical corticosteroids. A 12-month vehicle-controlled study of children with atopic dermatitis showed that early use of pimecrolimus reduced the frequency of flares from 51 percent to 28 percent,<sup>48</sup> although early use of mild topical corticosteroids might have shown similar effects.

Topical calcineurin inhibitors do not cause skin thinning. Both tacrolimus and pimecrolimus are associated with mild burning sensations when applied to the skin (Table 3). Five-year studies show a good safety profile for these agents.<sup>49</sup> In the United Kingdom, the National Institute of Clinical Excellence approves the use of topical tacrolimus for children older than two years of age with moderate-to-severe atopic dermatitis not controlled by topical corticosteroids, and of topical pimecrolimus as a second-line option for resistant dermatitis of the head and neck.<sup>50</sup> In the United States, both of these topical calcineurin inhibitors are approved as second-line agents, and the site of application is not restricted for pimecrolimus.

In March 2005, the Food and Drug Administration issued an alert to health care professionals concerning a potential link between topical pimecrolimus and tacrolimus and cancer (mainly lymphoma and skin cancer) on the basis of studies in animals, case reports, and knowledge of how these drugs work.<sup>51,52</sup> The alert emphasizes the importance of using these preparations only as labeled and when first-line treatment has failed or cannot be tolerated.

#### Other Topical Agents

A study of a refined-coal cream used on one side of the body in adults with mild-to-moderate atopic dermatitis as compared with 1 percent hydrocorti-

sone used on the other side suggested similar efficacy after four weeks.<sup>53</sup> There is insufficient evidence to conclude whether topical cromoglycate preparations are effective.<sup>30,54</sup> Other topical treatments — such as St. John's wort cream, vitamin B<sub>12</sub>, and licorice gel — whose use is supported by single small, randomized trials require further evaluation before they can be recommended for the treatment of atopic dermatitis.

#### Oral Antihistamines

Evidence is lacking to support the use of antihistamines for the treatment of atopic dermatitis,<sup>55</sup> although they are sometimes recommended for their sedative effects.<sup>56</sup> Reports on nonsedative antihistamines are conflicting.<sup>30,56,57</sup> The largest study failed to demonstrate any overall benefit from prolonged use of cetirizine in children with atopic dermatitis.<sup>58</sup>

#### Topical Doxepin

Topical doxepin produces some relief from itching within 48 hours. However, a clinically useful beneficial effect on disease severity has yet to be shown, and drowsiness may be a problem.<sup>30</sup>

#### Antibiotic Agents

Secondary infection with *S. aureus* is common (Fig. 3) and usually is treated with short courses of antibiotics such as floxacillin, cephalexin, or amoxicillin-clavulanate. One randomized trial found no benefit to prescribing floxacillin continually for four weeks as compared with placebo, and methicillin-resistant strains were more common in those who were prescribed antibiotics.<sup>59</sup> Although combinations of topical corticosteroids and antibiotics are used for atopic dermatitis, no good evidence suggests that they offer additional benefits as compared with topical corticosteroids alone.<sup>30</sup>

#### Ultraviolet Light

Randomized clinical trials have shown that ultraviolet light (ultraviolet B, narrow-band ultraviolet B, and high-intensity ultraviolet A) is beneficial for atopic dermatitis in the short term.<sup>30</sup> Burning and itching may occur, and carcinogenicity is a long-term concern. Phototherapy is usually used as a second- or third-line treatment.<sup>31</sup>

#### Immunosuppressive Agents

A brief course of oral corticosteroids (less than three weeks) may be used to control a flare of severe dis-

ease, although data from randomized clinical trials are lacking. Ongoing use of systemic immunosuppressive agents (oral corticosteroids, cyclosporine, azathioprine, mycophenolate, and interferon gamma) is limited by adverse effects and is usually reserved for people with severe disease who do not respond to other measures.<sup>30,43</sup>

#### Nonpharmacologic Approaches

Avoiding foods suspected to cause flares may be helpful in young children with severe disease, but usually is not helpful in adults.<sup>30,60</sup> Little evidence supports dietary exclusion of milk and eggs in unselected cases.<sup>61</sup> Some evidence supports egg-free diets in infants with atopic dermatitis who produce IgE antibodies to egg protein.<sup>60</sup> No good evidence supports highly restrictive diets, which can sometimes cause malnutrition.<sup>62</sup> Studies have failed to show clinically useful benefits from supplements such as evening primrose oil, borage oil,<sup>63</sup> zinc, pyridoxine, or vitamin E,<sup>30</sup> or from viable lactobacilli (probiotics).<sup>30,64</sup>

Small randomized trials support psychological approaches such as behavior therapy (to reduce the habit of scratching) and relaxation therapy.<sup>30</sup> Parental-education programs and demonstration of topical treatments by caregivers may be helpful.<sup>65,66</sup> Reduction of house-dust-mite allergen can reduce severity scores for atopic dermatitis, but the clinical relevance and sustainability of such reductions

is unknown.<sup>30</sup> Impermeable mattress covers are very effective in reducing levels of mite antigens, but they have no clear clinical benefit.<sup>67</sup>

No good evidence supports the use of bandages containing zinc paste. The use of "wet wraps" (an outer dry bandage overlying an inner damp bandage used over either emollients or topical corticosteroids) has become a popular second- or third-line measure for children with resistant atopic dermatitis but is not supported by randomized trials, and enhanced systemic absorption remains a concern.<sup>41</sup> No good data support alternative or complementary therapies such as homeopathy and bioresonance.<sup>30</sup>

#### AREAS OF UNCERTAINTY

Randomized trials are lacking to assess the benefits of many simple interventions, such as emollients and other nonpharmacologic approaches.<sup>30</sup> The lack of common outcome measures hinders meaningful comparisons across trials.<sup>11</sup> Trials with active comparators are needed to inform choices among agents.<sup>47</sup> Data on the optimal use of topical corticosteroids are needed, along with long-term data on adverse events. Data concerning the long-term safety of topical tacrolimus and pimecrolimus are also needed. The benefits of routine allergy testing require clarification. Moreover, it is unclear whether early aggressive therapy in children with atopic dermatitis alters the natural history of the disease.

#### GUIDELINES

The American Academy of Dermatology recently published evidence-based guidelines for atopic dermatitis that contain recommendations that are consistent with the evidence summarized in this article.<sup>43</sup> In addition, many useful Web sites are available (Table 4).

#### CONCLUSIONS AND RECOMMENDATIONS

Patients and families, such as the girl and her mother who are described in the vignette, often have concerns about topical corticosteroids that can be alleviated by appropriate education.<sup>68</sup> Patients and families should be taught about the course of atopic dermatitis; that is, that a single cause and cure are unlikely, although good control is nearly



**Figure 3. Acute, Secondary Infection in an Infant with Atopic Dermatitis.**

Widespread moist, exudative lesions and crusting are present.

**Table 4. Web Sites with Information about Eczema.**

**Evidence-based resources**

- http://www.ncchta.org/execsumm/summ437.htm  
National Health Service, United Kingdom, Health Technology Assessment systematic review
- http://libraries.nelh.nhs.uk/skin/default.asp  
Skin Conditions Specialist Library, National Electronic Library for Health, United Kingdom
- http://www.nottingham.ac.uk/dermatology/eczema/index.html  
Online diagnostic criteria manual

**Information for patients**

- http://www.aad.org/public/publications/pamphlets/eczemaatopicdermatitis.htm  
American Academy of Dermatology
- http://www.bad.org.uk/patients/disease/atopic/  
British Association of Dermatologists
- http://www.dermnetnz.org/dermatitis/treatment.html  
DermNet NZ (New Zealand)

**Support groups for patients**

- United States: http://www.nationaleczema.org/
- Canada: http://www.eczemahelp.ca/internal.htm
- United Kingdom: http://www.eczema.org/
- Australia: http://www.eczema.org.au/

always possible. Discussions should be supplemented by written information and a demonstration of the use of topical treatment.

For the girl in the vignette, I would recommend inducing a remission with once-daily application of a potent topical corticosteroid to the limbs and trunk for 10 days before scheduling a second visit to evaluate progress. Although data to support the use of emollients are limited, I would attempt to maintain remission by liberal use of emollients only, with recourse to five-day courses of potent or moderate-strength topical corticosteroids for flares.<sup>33</sup> If such a regimen failed to maintain adequate quality of life, I would introduce “weekend therapy” — that is, the application of a potent corticosteroid to new and previously active sites of atopic dermatitis each Saturday and Sunday evening to reduce flares.<sup>34</sup> Alternatively, intermittent use of topical tacrolimus or pimecrolimus may be used to reduce flares.<sup>50</sup> If facial dermatitis requires continual use of mild topical corticosteroids, I would recommend the use of topical tacrolimus, 0.03 percent, twice daily for three weeks and then once daily until the atopic dermatitis clears up.<sup>50</sup>

**REFERENCES**

1. Aoki T, Fukuzumi T, Adachi J, Endo K, Kojima M. Re-evaluation of skin lesion distribution in atopic dermatitis: analysis of cases 0 to 9 years of age. *Acta Derm Venereol Suppl (Stockh)* 1992;176:19-23.
2. Flohr C, Johansson SGO, Wahlgren CF, Williams HC. How atopic is atopic dermatitis? *J Allergy Clin Immunol* 2004;114:150-8.
3. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. *J Allergy Clin Immunol* 2004;113:832-6.
4. Williams HC, Wüthrich B. The natural history of atopic dermatitis. In: Williams HC, ed. *Atopic dermatitis: the epidemiology, causes, and prevention of atopic eczema*. Cambridge, United Kingdom: Cambridge University Press, 2000:41-59.
5. Bannister MJ, Freeman S. Adult-onset atopic dermatitis. *Australas J Dermatol* 2000;41:225-8.
6. Luoma R, Koivikko A, Viander M. Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years: a prospective study of 543 newborns. *Allergy* 1983;38:339-46.
7. Williams HC. What is atopic dermatitis and how should it be defined in epidemiological studies? In: Williams HC, ed. *Atopic dermatitis: the epidemiology, causes, and prevention of atopic eczema*. Cambridge, United Kingdom: Cambridge University Press, 2000:3-24.
8. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Dermatol Venereol (Stockh)* 1980;Suppl 92:44-7.
9. Williams HC, Burney PGJ, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol* 1994;131:406-16.
10. Williams HC. “Objective” measures of atopic dermatitis severity — in search of the Holy Grail. *Arch Dermatol* 2003;139:1490-2.
11. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? *J Invest Dermatol* 2003;120:932-41.
12. Emerson RM, Williams HC. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. *Br J Dermatol* 2000;142:288-97.
13. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-32.
14. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. *J Am Acad Dermatol* 2000;43:649-55.
15. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. *Br J Dermatol* 1998;139:73-6.
16. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. *Australas J Dermatol* 2004;45:16-22.
17. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. *Br J Dermatol* 2002;147:716-24.
18. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. *Pharmacoeconomics* 2003;21:105-13.
19. Rystedt I. Long term follow-up in atopic dermatitis. *Acta Derm Venereol Suppl (Stockh)* 1985;114:117-20.
20. Lammintausta K, Kalimo K, Raitala R, Forsten Y. Prognosis of atopic dermatitis: a prospective study in early adulthood. *Int J Dermatol* 1991;30:563-8.
21. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004;113:925-31.
22. Olesen AB, Juul S, Thestrup-Pedersen

- K. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. *Acta Derm Venereol* 2003;83:445-50.
23. Cookson WO, Moffatt ME. The genetics of atopic dermatitis. *Curr Opin Allergy Clin Immunol* 2002;2:383-7.
24. Williams HC. Atopic eczema — why we should look to the environment. *BMJ* 1995; 311:1241-2.
25. Leung DY, Bieber T. Atopic dermatitis. *Lancet* 2003;361:151-60.
26. Mar A, Marks R. Prevention of atopic dermatitis. In: Williams HC, ed. *Atopic dermatitis: the epidemiology, causes, and prevention of atopic eczema*. Cambridge, United Kingdom: Cambridge University Press, 2000: 205-20.
27. Sampson HA, Albergro R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. *J Allergy Clin Immunol* 1984;74:26-33.
28. Darsow U, Ring J. Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. *Clin Exp Dermatol* 2000;25:544-51.
29. Vender RB. The utility of patch testing children with atopic dermatitis. *Skin Therapy Lett* 2002;7:4-6.
30. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess* 2000;4:1-191.
31. McHenry PM, Williams HC, Bingham EA. Management of atopic eczema: Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. *BMJ* 1995;310:843-7.
32. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. *BMJ* 2002;324:768.
33. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol* 2002;147:528-37.
34. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ* 2003;326:1367.
35. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. *Pediatrics* 2000;105:794-9.
36. National Institute for Clinical Excellence. Final appraisal determination (FAD) for frequency of application of topical corticosteroids for atopic eczema. (Accessed May 9, 2005, at <http://www.nice.org.uk/page.aspx?o=115555>.)
37. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. *Clin Dermatol* 2003;21: 193-200.
38. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. *Br J Dermatol* 1999;140:1114-21.
39. Kyllonen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. *Br J Dermatol* 2004; 150:1174-81.
40. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. *J Dermatolog Treat* 2004; 15:169-78.
41. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. *Am J Clin Dermatol* 2002;3:141-7.
42. Patel L, Clayton PE, Addison GM, Price DA, David TJ. Linear growth in prepubertal children with atopic dermatitis. *Arch Dis Child* 1998;79:169-72.
43. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines." *J Am Acad Dermatol* 2004;50:391-404.
44. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. *Pediatr Dermatol* 1997;14:321-4.
45. Kantor I, Milbauer J, Psoner M, Weinstein IM, Simon A, Thormahlen S. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. *Today Ther Trends* 1993;11:157-66.
46. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. *BMJ* 2005;330:516-22.
47. Williams H. New treatments for atopic dermatitis. *BMJ* 2002;324:1533-4.
48. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics* 2002;110:e2.
49. Shainhouse T, Eichenfield LF. Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. *Expert Opin Drug Saf* 2003;2:457-65.
50. National Institute for Clinical Excellence. Final appraisal determination: tacrolimus and pimecrolimus for atopic eczema. (Accessed May 9, 2005, at [http://www.nice.org.uk/pdf/P&T\\_FAD.pdf](http://www.nice.org.uk/pdf/P&T_FAD.pdf).)
51. Center for Drug Evaluation and Research. Alert for healthcare professionals: pimecrolimus (marketed as Elidel). Rockville, Md.: Food and Drug Administration, March 2005. (Accessed May 9, 2005, at <http://www.fda.gov/cder/drug/InfoSheets/HCP/elidelHCP.htm>.)
52. *Idem*. Alert for healthcare professionals: tacrolimus (marketed as Protopic). Rockville, Md.: Food and Drug Administration, March 2005. (Accessed May 9, 2005, at <http://www.fda.gov/cder/drug/InfoSheets/HCP/ProtopicHCP.htm>.)
53. Munkvad M. A comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema. *Br J Dermatol* 1989; 121:763-6.
54. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. *Br J Dermatol* 2002;147: 299-307.
55. Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. *Dermatology* 2002;205:40-5.
56. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* 1999;135:1522-5.
57. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol* 2003; 148:1212-21.
58. Diepgen TL, Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol* 2002;13:278-86.
59. Ewing CI, Ashcroft C, Gibbs AC, Jones GA, Connor PJ, David TJ. Flucloxacillin in the treatment of atopic dermatitis. *Br J Dermatol* 1998;138:1022-9.
60. Sampson HA. The evaluation and management of food allergy in atopic dermatitis. *Clin Dermatol* 2003;21:183-92.
61. Fiocchi A, Bouygue GR, Martelli A, Terracciano L, Sarraud T. Dietary treatment of childhood atopic eczema/dermatitis syndrome (AEDS). *Allergy* 2004;59:Suppl 78: 78-85.
62. Liu T, Howard RM, Mancini AJ, et al. Kwashiorkor in the United States: fad diets,

CLINICAL PRACTICE

- perceived and true milk allergy, and nutritional ignorance. *Arch Dermatol* 2001;137:630-6.
63. Williams HC. Evening primrose oil for atopic dermatitis — time to say goodnight. *BMJ* 2003;327:1358-9.
64. Probiotics for atopic diseases. *Drug Ther Bull* 2005;43:6-8.
65. Staab D, von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. *Pediatr Allergy Immunol* 2002;13:84-90.
66. Gradwell C, Thomas KS, English JS, Williams HC. A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time? *Br J Dermatol* 2002;147:513-7.
67. Gutgesell C, Heise S, Seubert S, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. *Br J Dermatol* 2001;145:70-4.
68. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. *Clin Exp Dermatol* 2003;28:549-53.

*Copyright © 2005 Massachusetts Medical Society.*